RecruitingNCT06842407
Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
Sponsor
Checkmab S.r.l.
Enrollment
600 participants
Start Date
Apr 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- blood donors
- age of 18 years or more
- able to sign informed consent
Exclusion Criteria4
- age below 18 years
- Positive for HIV, HCV, HBV
- not suitable for blood donation
- not able to understand or sign informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06842407